Ultragenyx agreed to sell a rare pediatric priority review voucher (PRV) for $210 million, monetizing regulatory incentive value derived from its gene therapy GENGLYCOS (pariglasgene brecaparvovec-opnr) for glycogen storage disease type Ia. The transaction remains subject to customary closing conditions, including Hart-Scott-Rodino waiting-period expiration. The company framed the PRV sale as non-dilutive capital intended to accelerate its path toward first therapies for rare and ultra-rare diseases and profitability. Ultragenyx previously relied on PRV-generated financing, and the move continues to highlight how the PRV program can function like a funding bridge for specialty biotechs. For investors and dealmakers, the headline is the size and speed of value extraction from FDA incentive mechanics—an approach particularly relevant for companies without near-term large-scale revenue streams. While PRVs do not change clinical outcomes, they can materially affect runway and development choices, which in turn shapes how quickly late-stage assets can advance to pivotal trials.